Richard A. Miller M.D.

CIK: 0001031847

Transaction Breakdown

Open Market Buys (P)2 (40.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)1 (20.0%)

Derivative conversions

Awards (A)2 (40.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

CRVS

Corvus Pharmaceuticals, Inc.

DirectorOfficer

Discretionary Trading P&L

Holdings

Transaction History (5 total)

CRVS
Corvus Pharmaceuticals, Inc.
May 18, 2026
Purchase(P)
Indirect
5K shares at avg. $12.05$60K
CRVS
Corvus Pharmaceuticals, Inc.
May 18, 2026
Purchase(P)
Indirect
1.9K shares at avg. $12.01$23K
CRVS
Corvus Pharmaceuticals, Inc.
Dec 4, 2025
Award(A)
Stock Option (Right to Buy)
Direct
1M shares-
CRVS
Corvus Pharmaceuticals, Inc.
May 7, 2025
Exercise(M)
Direct
559.1K shares at avg. $3.50$2.0M
CRVS
Corvus Pharmaceuticals, Inc.
Dec 20, 2024
Award(A)
Stock Option (Right to Buy)
Direct
750K shares-

		Type	Shares	Price		Ownership
May 18, 2026	CRVS Corvus Pharmaceuticals, Inc.	Purchase(P)	5,000	$12.05	$60,250	Indirect
May 18, 2026	CRVS Corvus Pharmaceuticals, Inc.	Purchase(P)	1,932	$12.01	$23,203	Indirect
Dec 4, 2025	CRVS Corvus Pharmaceuticals, Inc.	Award(A) Stock Option (Right to Buy)	1,000,000	-	-	Direct
May 7, 2025	CRVS Corvus Pharmaceuticals, Inc.	Exercise(M)	559,073	$3.50	$1,956,756	Direct
Dec 20, 2024	CRVS Corvus Pharmaceuticals, Inc.	Award(A) Stock Option (Right to Buy)	750,000	-	-	Direct

1-5 of 5 transactions

About MILLER RICHARD A MD

MILLER RICHARD A MD (SEC CIK 0001031847) files insider reports with the SEC as President and CEO of Corvus Pharmaceuticals, Inc. (CRVS).

Signal8 holds 4 ownership filings by MILLER RICHARD A MD, all Form 4s, filed between Dec 23, 2024 and May 20, 2026. Those filings report 5 transactions, from Dec 20, 2024 to May 18, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on MILLER RICHARD A MD's filings is in BURLINGAME, CA.

Recent filings by MILLER RICHARD A MD

May 18, 2026: Open-market purchases of CRVS shares (2 lines, Form 4, code P).
Dec 4, 2025: Grant or award of CRVS derivative securities (Form 4, code A).
May 7, 2025: Option exercise of CRVS shares (Form 4, code M).
Dec 20, 2024: Grant or award of CRVS derivative securities (Form 4, code A).

Other insiders filing for Corvus Pharmaceuticals, Inc. (CRVS)

Moore David Scott, Director
CLARK IAN T, Director
Grais Linda, Director
Thompson Peter A., Director
van den Broek Richard, Director
Chan Andrew C., Director

How to read Form 4 transaction codes